Comparative Pharmacology
Head-to-head clinical analysis: CLINISOL 15 SULFITE FREE IN PLASTIC CONTAINER versus EPANOVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINISOL 15 SULFITE FREE IN PLASTIC CONTAINER versus EPANOVA.
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER vs EPANOVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids and calories for protein synthesis and energy metabolism in parenteral nutrition.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Intravenous infusion: 1.5 g/kg/day (amino acids) as part of parenteral nutrition; typical infusion rate 0.8-1.5 g/kg/hr.
4 g orally once daily as 4 capsules of 1 g each with food.
None Documented
None Documented
Amino acids have variable individual half-lives; the terminal elimination half-life for the amino acid mixture is approximately 1.5–2 hours, reflecting rapid distribution and metabolism; clinically, cessation of infusion leads to rapid decline in plasma amino acid levels.
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Renal (primarily as amino acids and metabolites); >90% of infused amino acids are eliminated via renal excretion as nitrogenous waste (urea, ammonia) and oxidized to CO2 and water; <10% excreted unchanged in bile/feces.
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution